ITP: Symptoms, Diagnosis and Care

What is immune thrombocytopenia?

Immune thrombocytopenic purpura, usually shortened to ITP, is now more commonly called immune thrombocytopenia. It is a condition in which the immune system mistakenly targets platelets, the small blood components that help seal injured blood vessels. Platelets may be removed from circulation too quickly, and production can also be reduced. The resulting low platelet count can make bleeding harder to stop. Not everyone develops visible purpura or has significant bleeding.

Children often recover within weeks or months, whereas adults are more likely to have a longer-lasting course. Some people need only monitoring, while others need treatment to reduce bleeding risk. A laboratory result is important, but it does not tell the whole story. Symptoms, other illnesses, medicines, age and upcoming procedures all help determine the plan. This guide explains those decisions without providing a personal diagnosis or a medication schedule. [1]

Primary and secondary ITP

Primary ITP means that clinicians have not identified another associated condition explaining the immune platelet problem. Secondary ITP occurs in association with another disorder, such as an autoimmune illness or certain infections. Separating these categories matters because care may need to address both the platelet problem and the associated disease.

ITP is a diagnosis of exclusion: there is no single routine test that proves it in every person. Clinicians consider the medical history, examination, complete blood count and blood film, then investigate alternatives as needed. They may assess for infections such as HIV or hepatitis C and, in appropriate circumstances, Helicobacter pylori. Testing is tailored to clinical context rather than ordered as an identical panel for everyone. A medicine-related platelet problem, inherited thrombocytopenia or abnormal platelet clumping in the sample may resemble ITP. Finding one of these possibilities can change the diagnosis and treatment. [2]

Newly diagnosed, persistent and chronic disease

The time labels used for ITP describe how long it has been present, not how frightened someone should be. Newly diagnosed ITP refers to the first three months. Persistent ITP lasts from three to twelve months, and chronic ITP continues beyond twelve months. These categories are useful when discussing follow-up and treatment choices, but they do not predict an individual outcome with certainty.

“Chronic” does not mean that severe bleeding is continuous, or that treatment must continue forever. Equally, a recent diagnosis is not automatically harmless. Platelet counts can fluctuate, so the clinical team looks at patterns alongside symptoms rather than expecting every result to match the previous one. A person whose blood count remains below the laboratory reference interval may still have a satisfactory treatment response if bleeding is controlled. Ask your clinician what successful management means in your particular situation. [3]

Symptoms: more than bruising

ITP may first be noticed through easy bruising, tiny flat spots called petechiae, nosebleeds, bleeding gums, or heavier menstrual bleeding. Dark blood-filled blisters inside the mouth can also occur. Other people have no obvious symptoms and learn about a low platelet count after a blood test for another reason. Skin changes alone cannot establish ITP, and their appearance varies with skin tone and how recently the bleeding occurred.

Tell the clinical team about bleeding that is new, increasing, taking longer to stop, or affecting everyday life. Useful details include where it happened, how long it lasted, whether there was an injury and whether you felt faint or short of breath. Menstrual bleeding should not be dismissed simply because it has become familiar. Record changes in flow and how often protection needs changing, then ask whether assessment for blood loss or iron deficiency is appropriate. [4]

ITP is not TTP, and purpura is a sign

Thrombotic thrombocytopenic purpura (TTP) is a different disorder despite the similar initials. In TTP, small clots form inside blood vessels, use up platelets and can damage organs. Red blood cells may also break apart. It is a medical emergency that requires a different diagnostic and treatment pathway. Confusion, neurological changes or serious illness alongside a low platelet count must not be casually attributed to familiar ITP.

Purpura itself describes bleeding into the skin, not a single disease. People can develop purpura for reasons other than immune platelet destruction, and a person can have ITP without prominent purpura. Our guide to purpura and its possible causes explains the broader skin finding. The practical distinction is simple: use the exact diagnosis given by the treating team, rather than substituting similar-sounding names. [5]

When bleeding needs emergency care

Head injuries need particular caution

A head injury deserves extra attention when someone has a bleeding disorder. Get urgent medical assessment after a significant blow to the head, even if the person initially appears well. Call emergency services for loss of consciousness, a seizure, new neurological symptoms, worsening drowsiness or difficulty waking. A headache that worsens or vomiting after injury also needs prompt assessment. Do not assume that the absence of a visible scalp wound excludes an internal injury.

Explain the platelet disorder immediately when contacting an emergency service. Describe what happened, whether there was a fall or collision, and any change from the person’s usual behavior. Follow the assessing clinician’s instructions about observation and returning for help; a generic online concussion checklist cannot determine the safest plan for someone with ITP. Parents, teachers, coaches and other caregivers should know whom to contact after an injury. [28]

How clinicians investigate a low platelet count

A complete blood count measures platelets as well as red and white blood cells. A peripheral blood film allows a laboratory professional to examine the cells directly, including their size and appearance. These results provide different kinds of information: the automated count supplies a number, while the film can reveal clues about why that number is abnormal.

The examination may include checking the skin and mouth for bleeding and looking for an enlarged liver or spleen. Depending on the findings, further tests can assess clotting, organ function or other suspected disorders. Bone marrow examination is not an automatic requirement for everyone with typical ITP. It may be considered when the clinical picture is unusual or another marrow condition needs to be investigated. Ask what question each proposed test is intended to answer. [8]

Bring a complete history, not just the latest result

A useful diagnostic visit includes a review of medicines and supplements, past illnesses, previous blood counts and any bleeding history. Mention products bought without a prescription as well as prescribed treatment. If a new medicine was started before the platelet count fell, tell the clinician when it began; do not decide independently that it caused ITP or abruptly stop an important prescription.

Bring previous results if they are available, because a longstanding pattern can mean something different from a sudden change. It is also helpful to describe whether relatives have unusual bleeding or low platelets. A diagnosis may be revisited if the course changes or treatment does not behave as expected. That is a reason for reassessment, not evidence that the patient has failed treatment. Before leaving, check who will review outstanding results and how you will receive them. [9]

Why the platelet count is not the only treatment trigger

Bleeding risk is not determined by one number alone. Clinicians also consider actual bleeding, previous serious bleeding, age, medicines that affect clotting, other health conditions, fall or injury risk, and planned procedures. Someone living far from urgent care may need a different practical plan from someone with easy access to a specialist. Preferences and treatment burdens belong in the discussion too.

This is why two people with similar counts may receive different advice. It does not necessarily mean that one clinician is ignoring the result. The aim is to prevent clinically important bleeding while avoiding unnecessary treatment harms. There is no universal internet threshold that tells every adult or child when to start therapy, go to hospital or resume a particular sport. Ask which factors matter most in your case and what changes would alter the plan. [10]

Observation is active care, especially in children

Watchful waiting means a planned approach to monitoring, not abandonment. For many children with no bleeding or only minor skin bleeding, observation avoids medicines whose burdens may exceed their immediate benefit. The pediatric recommendations in the ASH 2019 guideline support this approach, while emphasizing appropriate follow-up and education. Significant mucosal bleeding or impaired quality of life can change the balance.

An observation plan should explain when another blood count is needed, which symptoms require contact and what precautions apply. It should also make clear who is responsible for reviewing results. Families can ask what to do if an appointment is missed, the child develops an infection or the usual clinical team cannot be reached. Adults may also be monitored without immediate treatment in selected circumstances, but a child’s plan should never be copied directly into adult care. [11]

Treatment choices: a shared and changing decision

ASH’s 2026 adult guidance updates initial and second-line treatment for primary ITP. It introduces conditional preferences for selected combination approaches at initial treatment rather than assuming that corticosteroids alone are always the best option. These may pair a corticosteroid with rituximab or a platelet-production treatment. Conditional recommendations require discussion of evidence, benefits, harms and patient preferences; they are not instructions for everyone to receive the same combination.

After first-line corticosteroids have failed, the update favors a thrombopoietic agent, with rituximab or other alternatives selected according to suitability. The 2026 adult update should not be presented as a pediatric guideline or as a complete emergency or pregnancy protocol. Ask whether the proposed treatment is intended to work quickly, maintain a response, reduce reliance on steroids or meet a short-term need such as surgery. Also ask what will happen if it does not work. [12]

Corticosteroids and treatment monitoring

Corticosteroids reduce immune activity and are commonly used in ITP. Their potential benefit must be balanced against adverse effects, including sleep disturbance, mood changes, high blood pressure, digestive problems and changes in blood sugar. Longer exposure can bring additional burdens. A short intended course still deserves a clear explanation of what to expect and which symptoms to report.

Tell the prescriber about diabetes, troublesome anxiety or mood symptoms, previous steroid problems and other relevant conditions. If sleep, behavior or daily functioning changes during treatment, contact the team rather than assuming that these effects must simply be endured. Follow the prescribed stopping or tapering instructions; this article does not provide a schedule. Repeated courses should prompt discussion of the longer-term strategy instead of becoming an unexamined routine. Treatment review should ask both whether bleeding has improved and whether the treatment itself is making life harder. [13]

IVIG and short-term platelet support

Intravenous immunoglobulin, or IVIG, is an infusion of antibodies prepared from donated plasma. In ITP it can help raise the platelet count relatively quickly, which may be useful when a more rapid response is needed. The benefit is often temporary, so a good immediate result does not necessarily settle the longer-term treatment question.

Infusion reactions and headache are among the issues discussed before treatment. A severe headache, neck stiffness or other concerning symptoms after an infusion require medical advice rather than being dismissed as routine. Tell the infusion team promptly if you feel unwell during administration. Platelet transfusions are not a routine long-term solution to immune platelet destruction, but clinicians may use them as part of urgent care for major bleeding or selected procedural situations. Emergency treatment can combine approaches. [14]

Romiplostim: stimulating platelet production

Romiplostim, marketed as Nplate, is a thrombopoietin receptor agonist. It is given by injection, not as a tablet. Its United States labeling covers particular adults and children with ITP after an insufficient response to specified previous treatments, with age and disease-duration conditions for pediatric use. The label does not describe it as a way to normalize every platelet count.

The specialist adjusts treatment using blood counts and the clinical situation. Important discussions include clotting risk, monitoring requirements and what happens when treatment is interrupted or stopped. A medicine that raises platelets does not make it safe to ignore chest pain, sudden breathlessness or neurological symptoms. Ask how administration will fit into work, school or travel, and who to contact if an appointment cannot be kept. The practical demands of an injectable treatment can matter as much as its name when comparing options. [15]

Eltrombopag: food and medicine interactions matter

Eltrombopag, known as Promacta in the United States, is an oral platelet-production treatment used for eligible patients with persistent or chronic ITP after an insufficient response to specified therapies. It also has other indications, so a prescription or online drug description must be interpreted in the context of the condition being treated. Tablet and suspension instructions should be checked for the exact product supplied.

Food, calcium-containing products, antacids and mineral supplements can affect absorption. The pharmacist should explain how the prescribed medicine fits around meals and other products; do not invent a timing plan from a general article. Liver monitoring and discussion of clotting risk are important parts of care. Tell the team about liver disease, pregnancy plans and every supplement you take. If adherence is difficult because of dietary restrictions or daily routines, say so. [16]

Avatrombopag: another oral option

Avatrombopag, marketed as Doptelet, is another thrombopoietin receptor agonist. Its current United States labeling includes adult chronic ITP and specified pediatric persistent or chronic ITP after an insufficient response to previous treatment. Formulation and eligibility depend on age and indication. This is different from its separate use for some adults with chronic liver disease before a procedure.

Blood-count monitoring remains necessary even when a medicine is taken at home. The label warns about thrombotic and thromboembolic complications, meaning unwanted blood clots. Other medicines can affect treatment, so check new prescriptions with the prescriber or pharmacist. Do not assume that two oral platelet-production medicines can be swapped without a new plan. When comparing options, discuss the exact formulation, monitoring, access and likely treatment burden. [17]

Fostamatinib: reducing immune platelet destruction

Fostamatinib, marketed as Tavalisse in the United States, acts through spleen tyrosine kinase signaling. It is an option for adults with chronic ITP who have not responded sufficiently to previous treatment. Unlike treatments designed primarily to stimulate production, it targets a pathway involved in immune platelet destruction. That difference is one reason the specialist may discuss it when reviewing an individual’s previous responses.

Monitoring includes attention to blood pressure, liver tests and blood cell counts. Diarrhea, liver-test abnormalities, high blood pressure and reduced neutrophils are among the safety issues considered. Report troublesome symptoms and keep monitoring appointments rather than adjusting treatment yourself. Pregnancy risk and medicine interactions also need review before and during treatment. The most useful comparison is not whether one mechanism sounds more advanced, but whether the expected benefits and risks fit the person. [18]

Rilzabrutinib: an approved newer treatment, not a cure

Rilzabrutinib, marketed as Wayrilz, received United States approval in 2025 for adults with persistent or chronic ITP after an insufficient response to a previous treatment. It is a Bruton’s tyrosine kinase inhibitor. This is an approved option for a defined population, not a reason to describe every newer ITP treatment as experimental, or to promise a cure.

The prescribing information warns about serious infections, liver injury and potential harm to an unborn baby. It also identifies important interactions, including with some acid-reducing medicines and drugs affecting specific liver-enzyme pathways. A full medication review and the recommended testing are therefore part of treatment selection. Tell the team about pregnancy plans, breastfeeding, kidney or liver problems, and new symptoms. Availability and authorized use differ between countries. Being newer does not make a medicine automatically preferable to established options, and an adult indication must not be generalized to children. The choice remains a specialist, patient-specific decision. [19]

Splenectomy requires a long-term prevention plan

Removing the spleen can be considered in selected people with ITP, but it is a substantial decision rather than a routine next step after one disappointing blood count. The spleen contributes to immune defense, so surgery creates lasting infection-prevention responsibilities. Other treatments and the possibility of future changes in the illness need to be considered before an irreversible operation.

People without a functioning spleen need advice about recommended vaccinations, antibiotics where indicated, and urgent action for symptoms of infection. The increased risk of serious infection does not disappear after recovery from surgery. Ask for a written plan, appropriate medical identification and guidance for travel or animal bites. Surgical recovery also requires its own advice about activity and clot prevention. A good discussion covers life after the operation, not just the chance that platelets will rise. [20]

Children: protect normal life as well as physical safety

Many children improve without needing prolonged treatment, but follow-up remains important. The aim is to keep the child safe without treating every ordinary activity as dangerous. School attendance, play and friendships should be discussed with the clinical team. Restrictions depend on the child’s situation, the risk of injury and the current advice, rather than on a parent’s interpretation of an online table.

Give teachers and caregivers a clear care plan that explains whom to call for bleeding or a head injury. They do not need to become platelet-count experts. Ask the team to distinguish normal daily play from activities involving a substantial risk of collisions, head trauma or serious bruising. Support a child who feels anxious or excluded, and tell clinicians if restrictions are disrupting sleep, school or family life. A reassuring prognosis should not silence genuine distress. [7]

Medication and procedure safety for families

Aspirin and nonsteroidal anti-inflammatory drugs such as ibuprofen can increase bleeding concerns in children with ITP. Ask a clinician or pharmacist which pain or fever medicine is appropriate. Some herbal products also interfere with bleeding or prescribed treatment, so “natural” does not mean risk-free. Keep a current medicine list that includes nonprescription products.

Tell dentists and other clinicians about the low platelet count before treatment. A planned extraction, injection or operation may need coordination with hematology; do not cancel necessary care without discussing how it can be provided safely. Parents should also ask about infection exposures when a child is receiving medicines that suppress immunity. Before travel, check how follow-up and urgent care will work and whether insurance covers the condition. The same principle applies to school trips: plan access to help rather than relying on an informal promise that someone will “keep an eye” on the child. [21]

Pregnancy: planning across specialties

ITP does not automatically prevent pregnancy, but it should be discussed before conception when possible. Hematology and maternity teams can review current medicines, previous bleeding and the likely monitoring plan. If pregnancy has already begun, contact the treating team promptly rather than stopping treatment independently. Regular blood counts help guide decisions as pregnancy progresses.

A low platelet count during pregnancy is not automatically ITP. Clinicians consider other causes and may arrange additional tests. Many people with known ITP do not need treatment throughout pregnancy, while others need treatment because of bleeding or preparations for delivery. Decisions about medication must account for both parent and baby. Ask who will coordinate the plan, how results will be shared and when the birth team will review it. Clear communication is particularly important when different hospitals provide specialist and maternity care. A general adult treatment list cannot determine which medicine is suitable during pregnancy or breastfeeding. [22]

Birth and the newborn need their own plan

Maternal antibodies can cross the placenta and sometimes lower a newborn’s platelet count. The baby’s assessment is therefore part of the care plan, even if the mother feels well. The maternity and pediatric teams decide how to check the baby and whether repeat testing or treatment is needed. Parents should understand who will review the results after birth and what follow-up has been arranged.

Do not assume that the mother’s latest platelet count predicts the baby’s exact result. The infant’s situation is assessed separately. Ask how the team will communicate any concerns, particularly if mother and baby leave hospital at different times. Postnatal appointments should also review the mother’s bleeding, medicines and ongoing blood counts. A birth plan is not complete if it stops at delivery and overlooks the days afterward. [23]

Delivery, anesthesia and other pregnancy diagnoses

Pregnancy-related thrombocytopenia includes several different conditions. Gestational thrombocytopenia is often mild, whereas disorders such as preeclampsia and HELLP syndrome can require urgent specialist care. New severe symptoms in pregnancy should not simply be attributed to an existing ITP diagnosis. The obstetric team evaluates the whole clinical picture, including symptoms, examination and laboratory results.

Decisions about delivery and anesthesia require a current, individualized assessment. An online platelet threshold cannot guarantee that an epidural, spinal anesthetic or particular delivery method will be appropriate. Ask the maternity team when anesthesia review should occur and how the plan will be updated if counts change. A written contingency plan is especially useful when treatment may be needed near delivery. Continue follow-up after birth because platelet disorders and treatment needs do not necessarily resolve immediately. For urgent pregnancy symptoms, use the maternity service’s emergency instructions or local emergency services rather than waiting for a routine hematology response. [27]

Living well with ITP: a practical safety routine

Keep follow-up appointments and take treatment as prescribed. Let the healthcare team know about new bleeding, possible infection and changes in other medicines. Adults prescribed aspirin, an antiplatelet medicine or an anticoagulant for another condition need coordinated advice: do not abruptly stop a medicine intended to prevent a stroke or clot because an online guide mentions bleeding risk.

Before dental work or surgery, make sure the procedural team knows about ITP and can speak with hematology when necessary. Carry a concise record of the diagnosis, medicines and relevant contact numbers. For exercise, choose activities with advice tailored to your injury risk and current situation rather than assuming that all movement must stop. During travel, know where urgent care is available and keep medicines accessible. These habits do not eliminate every risk, but they make it easier to respond promptly. The safest routine is one the patient can actually follow, not an elaborate plan that fails during work, school or holidays. [24]

Fatigue and emotional strain deserve attention

Fatigue can interfere with concentration, work and relationships even when there is no obvious bleeding. Do not assume that every episode of tiredness is caused by the platelet count. Sleep problems, stress, iron deficiency and other medical conditions can contribute. Persistent or worsening fatigue should be discussed with a clinician, especially when it affects daily life or occurs with other symptoms.

A short diary can help show when tiredness occurs, how sleep has been, and whether symptoms changed after treatment. Describe the impact in concrete terms, such as needing to rest after ordinary tasks or struggling to complete a school day. This is more informative than saying only that energy is “low.” Ask about manageable activity, sleep routines and support for anxiety or low mood. Emotional support is not a suggestion that symptoms are imaginary. Living with unpredictable results can be difficult, and addressing that burden is part of sensible care rather than an optional extra after the laboratory numbers improve. [25]

Research, remission and realistic expectations

Clinical trials can offer access to carefully monitored research, but participation is not the same as receiving a proven better treatment. Eligibility rules, possible benefits, risks, extra visits and alternatives should be explained through informed consent. Ask what is known, what remains uncertain, whether treatment allocation is randomized and who will handle ordinary ITP care during the study.

Patients should also understand whom to contact for an urgent problem and what happens if participation ends. A study listing or promotional headline does not guarantee suitability, access or benefit. Discuss research opportunities with a clinician who understands your disease history. More broadly, a treatment response, remission and a permanent cure are different ideas. Good educational information should not promise that a particular diet, supplement or newly announced medicine will permanently remove the disease. The useful question is whether an option can improve meaningful outcomes for this person, with acceptable harms and a plan for reassessment. [26]

Questions to take to your next appointment

Write down the two or three issues that matter most before the appointment. For example: “What is the main reason you recommend treatment now?” “What changes should make me call the same day?” and “How will we judge whether this plan is working?” If the explanation is unclear, ask the clinician to describe it in ordinary language and repeat the plan back in your own words.

Bring a list of forthcoming dental appointments, procedures, travel and activities that might affect planning. Ask who will send results, whether you need to book the next blood test yourself and which service handles questions outside office hours. If cost, transport, school absence or difficulty taking a medicine could prevent following the plan, say so early. These are practical barriers the team needs to understand, not personal failings. Leave with the next step and a contact route written down. This article can help prepare that conversation, but your treating team must decide the care appropriate to you.

At a glance: different questions need different answers

Sources

Sources checked October 21, 2026. References support the numbered sections above. Drug approvals and availability differ by country; prescribing information is not a self-treatment guide.

1. NHLBI: Immune thrombocytopenia
2. International consensus report: investigation and management of primary ITP
3. Hull University Teaching Hospitals: ITP
4. King’s College Hospital: ITP patient information
5. NHLBI: Thrombotic thrombocytopenic purpura
6. NHLBI: Thrombocytopenia
7. Cambridge University Hospitals: ITP information for parents
8. NHLBI: Diagnosing platelet disorders
9. Mayo Clinic: ITP diagnosis and treatment
10. ASH: Choosing Wisely, ITP treatment decisions
11. ASH: 2019 ITP guidelines
12. ASH: 2026 adult ITP guidelines and implementation resources
13. NHLBI: Platelet disorder treatments
14. Cambridge University Hospitals: ITP treatments
15. DailyMed: Nplate (romiplostim) prescribing information
16. DailyMed: Promacta (eltrombopag) prescribing information
17. DailyMed: Doptelet (avatrombopag) prescribing information
18. DailyMed: Tavalisse (fostamatinib) prescribing information
19. FDA: Wayrilz (rilzabrutinib) prescribing information
20. NHS: Spleen problems and spleen removal
21. Evelina London: ITP in children
22. King’s College Hospital: ITP in pregnancy
23. Oxford University Hospitals: ITP in pregnancy
24. NHLBI: Living with platelet disorders
25. NHS: Tiredness and fatigue
26. NIMH: Clinical research trials, questions and answers
27. NHLBI: Pregnancy and platelet disorders
28. NHS: Head injury and concussion